Heymann, D. orcid.org/0000-0001-7777-0669, Heymann, M.F. and Brown, H.K. (2015) Drugs in early clinical development for the treatment of osteosarcoma. Expert Opinion on Investigational Drugs. ISSN 1354-3784
Abstract
Introduction: Osteosarcomas are the main malignant primary bone tumours found in children and young adults. Conventional treatment is based on diagnosis and resection surgery, combined with polychemotherapy. This is a protocol that was established in the 1970s. Unfortunately, this therapeutic approach has reached a plateau of efficacy and the patient survival rate has not improved in the last four decades. New therapeutic approaches are thus required to improve the prognosis for osteosarcoma patients. Areas covered: From the databases available and published scientific literature, the present review gives an overview of the drugs currently in early clinical development for the treatment of osteosarcoma. For each drug, a short description is given of the relevant scientific data supporting its development. Expert opinion: Multidrug targeted approaches are set to emerge, given the heterogeneity of osteosarcoma subtypes and the multitude of therapeutic responses. The key role played by the microenvironment in the disease increases the number of therapeutic targets (such as macrophages or osteoclasts), as well as the master proteins that control cell proliferation or cell death. Ongoing phase I/II trials are important steps, not only for identifying new therapies with greater safety and efficacy, but also for better defining the role played by the microenvironment in the pathogenesis of osteosarcoma.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2016 Taylor & Francis. This is an author produced version of a paper subsequently published in Expert Opinion on Investigational Drugs. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | Clinical Trials; Immunotherapy; Macrophages; Microenvironment; Osteosarcoma; Immunomodulation; Cancer-Initiating Cells |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) |
Funding Information: | Funder Grant number BONE CANCER RESEARCH TRUST BCRT 4516 |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 19 Sep 2016 10:15 |
Last Modified: | 26 Sep 2017 01:35 |
Published Version: | http://dx.doi.org/10.1080/13543784.2016.1237503 |
Status: | Published |
Publisher: | Taylor & Francis |
Refereed: | Yes |
Identification Number: | 10.1080/13543784.2016.1237503 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:104826 |